Arkolith/Insider Trading/SUPN/Form 4

Gemayel Georges

DirectorSUPERNUS PHARMACEUTICALS, INC. (SUPN) · full profile →Form 4 · filed Mar 9, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.0M
Net Open-Market Flow
-$1.0M
Transactions
4
3 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 6, 2026Sell(S)9K$53.00$466K27K
Mar 6, 2026Option exercise(M)8K$25.30$200K36K
Mar 5, 2026Sell(S)10K$53.71$537K28K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 6, 2026Option exercise(M)8K—$00

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001256088-26-000006) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML